This topic contains a solution. Click here to go to the answer

Author Question: When assessing for therapeutic effects of mitotane in a patient with adrenocortical carcinoma, the ... (Read 236 times)

Mimi

  • Hero Member
  • *****
  • Posts: 542
When assessing for therapeutic effects of mitotane in a patient with adrenocortical carcinoma, the nurse should expect to identify
 
  A) a decrease in agitation.
  B) an audible S3.
  C) a decrease in blood pressure.
  D) a decrease in urine output.

Question 2

_________________ __________________ ________________ glaucoma is an acute eye disease that requires emergency surgery.
 
  Fill in the blank(s) with correct word



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

nital

  • Sr. Member
  • ****
  • Posts: 320
Answer to Question 1

C
Feedback:
A decrease in blood pressure is an expected therapeutic effect of mitotane. An audible S3 is not expected. Mitotane does not address agitation or high urine output.

Answer to Question 2

Closed-angle




nital

  • Sr. Member
  • ****
  • Posts: 320

 

Did you know?

All adverse reactions are commonly charted in red ink in the patient's record and usually are noted on the front of the chart. Failure to follow correct documentation procedures may result in malpractice lawsuits.

Did you know?

Illness; diuretics; laxative abuse; hot weather; exercise; sweating; caffeine; alcoholic beverages; starvation diets; inadequate carbohydrate consumption; and diets high in protein, salt, or fiber can cause people to become dehydrated.

Did you know?

About 3.2 billion people, nearly half the world population, are at risk for malaria. In 2015, there are about 214 million malaria cases and an estimated 438,000 malaria deaths.

Did you know?

Elderly adults are at greatest risk of stroke and myocardial infarction and have the most to gain from prophylaxis. Patients ages 60 to 80 years with blood pressures above 160/90 mm Hg should benefit from antihypertensive treatment.

Did you know?

Barbituric acid, the base material of barbiturates, was first synthesized in 1863 by Adolph von Bayer. His company later went on to synthesize aspirin for the first time, and Bayer aspirin is still a popular brand today.

For a complete list of videos, visit our video library